Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Pharmacogenetics Testing: Discussion of Industry Experts sponsored by Luminex

Reporter: Aviva Lev-Ari, PhD, RN

“Pharmacogenetics: A Discussion with Industry Experts about the State of Affairs and Clinical Application“

SOURCE

http://cdn2.hubspot.net/hubfs/128032/PGx/pharmacogenetics-a-discussion-with-industry-experts-about-the-state-of-affairs-and-clinical-application-luminex-corp.pdf?t=1433269929556

Sponsored by Luminex 

Luminex launched its first test to aid in personalized medicine in 2010. Since that time, Luminex has received Health Canada Approval and U.S. FDA clearance, and CE Mark for its xTAG® CYP2D6 Kit v3 and xTAG® CYP2C19 Kit v3 assays, and is a member of the Personalized Medicine Coalition.

For more information on Luminex’s pharmacogenetic assays, visit: www.luminexcorp.com/CYP2D6 or www.luminexcorp.com/CYP2C19. Learn more about the Personalized Medicine Coalition: www.personalizedmedicinecoalition.org

LIST OF EXPERTS

Scott W. Blevins, RPh, MBA; President and COO, GENETWORx: Mr. Blevins has over 20 years of experience in the healthcare industry, with an emphasis in providing consultative services to physicians, including clinical and physician practice management advice. Prior to becoming a healthcare business consultant, Mr. Blevins worked in various segments of the pharmacy industry, which included chain, independent, long-term care facility dispensing and consulting, and Pharmacy Benefit Management (PBM). Mr. Blevins also has a working knowledge of Healthcare Information Technology, Revenue Cycle Management, and Laboratory Services through his ownership interest in “Docs Billing Solutions.” Mr. Blevins is a co-founder of GENETWORx. Mr. Blevins received his Bachelors of Science degree in Pharmacy from the Medical College of Virginia (M.C.V.) School of Pharmacy, and his Master’s in Business Administration degree from the E. Claiborne Robins School of Business at the University of Richmond.

Sarah Jacobs-Helber, PhD, HCLD (ABB); Laboratory Director, GENETWORx: Dr. Jacobs-Helber has over 20 years of clinical and laboratory experience in the field of genetics. She has authored a large number of peer-reviewed papers in the course of her research into the biology and genetics of cancer at both the National Institutes of Health and Virginia Commonwealth University. She has been in the clinical genetic testing area since 2006. She holds board-certification as a High-Complexity Clinical Laboratory Director (HCLD) from the American Board of Bioanalysts and is certified in molecular genetic testing by the State of New York.

Joan Kegerize, MS, JD, CPC; Principal Consultant, GMBI Consulting: Ms. Kegerize specializes in reimbursement and coding strategies, with emphasis in genetic services and diagnostic laboratory molecular pathology procedures. She has extensive experience in molecular diagnostic testing and reimbursement and works closely with manufacturers, laboratories, and industry to direct and implement reimbursement strategies for Medicare, Medicaid, and commercial payers. Ms. Kegerize received her genetic counseling training at the University of Pittsburgh Genetic Counseling Program. She earned her Juris Doctor degree from New York Law School and is admitted to the Bar in the state of New Jersey. Ms. Kegerize obtained certification as a Certified Professional Coder by the American Academy of Professional Coders.

The Panelists SB SJH 5 © 2015 Luminex Corporation. All rights reserved. The trademarks mentioned herein are the property of Luminex or their respective owners.

ANSWERS to the following questions are to be found at

http://cdn2.hubspot.net/hubfs/128032/PGx/pharmacogenetics-a-discussion-with-industry-experts-about-the-state-of-affairs-and-clinical-application-luminex-corp.pdf?t=1433269929556

LIST OF QUESTIONS

1. Why do laboratories decide to offer pharmacogenetic testing and services in the first place?
2. What does GENETWORx do to increase utilization of pharmacogenetic testing by physicians and providers?
3. What are the challenges of pharmacogenetics implementation, and how are different laboratories overcoming these obstacles?
4. How does using an FDA-cleared assay simplify the implementation process?
5. How have the changes in reimbursement affected the landscape?
6. How have changes in reimbursement affected the way laboratories perform?
7. What is the future of pharmacogenetics testing?